{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:40:48Z","timestamp":1795012848101,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Nutr"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41430-025-01589-y","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T05:29:29Z","timestamp":1742621369000},"page":"715-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A systematic review of the impact of Elexacaftor\/Tezacaftor\/Ivacaftor on body composition in people with cystic fibrosis"],"prefix":"10.1038","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9789-574X","authenticated-orcid":false,"given":"Laura","family":"Kinsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Winterbottom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4967-647X","authenticated-orcid":false,"given":"Sorrel","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"key":"1589_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.genom.6.080604.162254","volume":"6","author":"GR Cutting","year":"2005","unstructured":"Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genom Hum Genet. 2005;6:237\u201360.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jcf.2019.08.015","volume":"18","author":"M Litvin","year":"2019","unstructured":"Litvin M, Yoon JC, Leey Casella J, Blackman SM, Brennan AL. Energy balance and obesity in individuals with cystic fibrosis. J Cyst Fibro. 2019;18:S38\u2013S47.","journal-title":"J Cyst Fibro."},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ccm.2007.02.006","volume":"28","author":"CE Milla","year":"2007","unstructured":"Milla CE. Nutrition and Lung Disease in Cystic Fibrosis. Clin Chest Med. 2007;28:319\u201330.","journal-title":"Clin Chest Med."},{"key":"1589_CR4","unstructured":"World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. 2000. https:\/\/iris.who.int\/handle\/10665\/42330. Accessed 28th January 2025."},{"key":"1589_CR5","doi-asserted-by":"crossref","unstructured":"Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Bailey KR, Collazo-Clavell MD, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes. 2010; 32:959\u201366.","DOI":"10.1038\/ijo.2008.11"},{"key":"1589_CR6","unstructured":"National Institute for Health and Care Excellence. Weight management: lifestyle services for overweight or obese children and young people. PH47. https:\/\/www.nice.org.uk\/guidance\/ph47. Accessed 17\/12\/24."},{"key":"1589_CR7","doi-asserted-by":"crossref","unstructured":"Davis LL, Nolan MZ. The influence of obesity on care of adults with cardiovascular Disease. Nurs Clin North Am. 2021; 56:511\u201325.","DOI":"10.1016\/j.cnur.2021.07.002"},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.nut.2018.03.052","volume":"55-56","author":"P Calella","year":"2018","unstructured":"Calella P, Valerio G, Brodlie M, Donini LM, Siervo MD. Cystic fibrosis, body composition, and health outcomes: a systematic review. Nutrition. 2018;55-56:131\u20139.","journal-title":"Nutrition"},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1378\/chest.124.6.2220","volume":"124","author":"AA Ionescu","year":"2003","unstructured":"Ionescu AA, Evans WD, Pettit RJ, Nixon LS, Stone MD, Shale DJ. Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis. Chest. 2003;124:2220\u20138.","journal-title":"Chest."},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.clnesp.2022.01.027","volume":"48","author":"LLGC Ackermans","year":"2022","unstructured":"Ackermans LLGC, Rabou J, Basrai M, Schweinlin A, Bischoff SC, Cussenot O, et al. Screening, diagnosis, and monitoring of sarcopenia: When to use which tool? Clin Nutr Espen. 2022;48:36\u201344.","journal-title":"Clin Nutr Espen"},{"key":"1589_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16\u201331.","journal-title":"Age Ageing."},{"key":"1589_CR12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.jacc.2010.11.058","volume":"57","author":"T Coutinho","year":"2011","unstructured":"Coutinho T, Goel K, Corr\u00eaa De S\u00e1 D, Kragelund C, Kanaya AM, Zeller M, et al. Central Obesity and Survival in Subjects With Coronary Artery Disease. J Am Coll Cardiol. 2011;57:1877\u201386.","journal-title":"J Am Coll Cardiol."},{"key":"1589_CR13","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/ije\/dyt208","volume":"42","author":"CJ Patel","year":"2013","unstructured":"Patel CJ, Rehkopf DH, Leppert JT, Bortz WM, Cullen MR, Chertow GM, et al. Systematic evaluation of environmental and behavioural factors associated with all-cause mortality in the United States National Health and Nutrition Examination Survey. Int J Epidemiol. 2013;42:1795\u2013810.","journal-title":"Int J Epidemiol."},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pcad.2018.06.004","volume":"61","author":"M Pich\u00e9","year":"2018","unstructured":"Pich\u00e9 M, Poirier P, Lemieux I, Despres J. Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update. Prog Cardiovasc Dis. 2018;61:103\u201313.","journal-title":"Prog Cardiovasc Dis."},{"key":"1589_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1259\/bjr\/38447238","volume":"85","author":"A Shuster","year":"2012","unstructured":"Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radio. 2012;85:1\u201310.","journal-title":"Br J Radio."},{"key":"1589_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/ajcn\/85.1.40","volume":"85","author":"A De Lorenzo","year":"2007","unstructured":"De Lorenzo A, Gobbo VD, Premrov MG, Bigioni M, Galvano F, Di Renzo LD, et al. Normal-weight obese syndrome: early inflammation? Am J Clin Nutr. 2007;85:40\u20135.","journal-title":"Am J Clin Nutr."},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","volume":"32","author":"JA Alvarez","year":"2016","unstructured":"Alvarez JA, Ziegler TR, Millson EC, Stecenko AA. Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity. Nutrition. 2016;32:447\u201352.","journal-title":"Nutrition."},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/nu14020310","volume":"14","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Jay LT, Freedman S, Sawicki GS, Uluer A, Finkelstein JS, et al. The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Nutrients. 2022;14:310\u201321.","journal-title":"Nutrients"},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jcf.2019.01.002","volume":"18","author":"MP Bellissimo","year":"2019","unstructured":"Bellissimo MP, Zhang I, Ivie EA, Phong HT, Tangpricha V, Hunt WR, et al. Visceral adipose tissue is associated with poor diet quality and higher fasting glucose in adults with cystic fibrosis. J Cyst Fibro. 2019;18:430\u20135.","journal-title":"J Cyst Fibro."},{"key":"1589_CR20","doi-asserted-by":"publisher","unstructured":"Willett W, Hu F. Anthropometric Measures and Body Composition. In: Nutritional Epidemiology. 3rd edn (online edn - 2013) Oxford Academic. pp 213\u201340. https:\/\/doi.org\/10.1093\/acprof:oso\/9780199754038.003.0009, Accessed 30 Dec. 2024.","DOI":"10.1093\/acprof:oso\/9780199754038.003.0009"},{"key":"1589_CR21","first-page":"566","volume":"11","author":"SY Lee","year":"2008","unstructured":"Lee SY, Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care. 2008;11:566\u201372.","journal-title":"Curr Opin Clin Nutr Metab Care."},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ejcn.2017.27","volume":"71","author":"A Bosy-Westphal","year":"2017","unstructured":"Bosy-Westphal A, Jensen B, Braun W, Pourhassan M, Gallagher D, Muller MJ. Quantification of whole-body and segmental skeletal muscle mass using phase-sensitive 8-electrode medical bioelectrical impedance devices. Eur J Clin Nutr. 2017;71:1061\u20137.","journal-title":"Eur J Clin Nutr."},{"key":"1589_CR23","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.3390\/s19224825","volume":"19","author":"T Cannon","year":"2019","unstructured":"Cannon T, Choi J. Development of a Segmental Bioelectrical Impedance Spectroscopy Device for Body Composition Measurement. Sensors. 2019;19:4825\u2013942.","journal-title":"Sensors."},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/nu14050965","volume":"14","author":"D Lopez-Gonzalez","year":"2022","unstructured":"Lopez-Gonzalez D, Wells JCK, Clark P. Body Composition Assessment in Mexican Children and Adolescents. Part 2: Cross-Validation of Three Bio-Electrical Impedance Methods against Dual X-ray Absorptiometry for Total-Body and Regional Body Composition. Nutrients. 2022;14:965\u201372.","journal-title":"Nutrients."},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/ajcn\/52.6.953","volume":"52","author":"TB Vanitallie","year":"1990","unstructured":"Vanitallie TB, Yang MU, Heymsfield SB, Funk RC, Boileau RA. Height-normalized indices of the body\u2019s fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr. 1990;52:953\u20139.","journal-title":"Am J Clin Nutr."},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clnu.2016.09.004","volume":"36","author":"T Cederholm","year":"2017","unstructured":"Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36:49\u201364.","journal-title":"Clin Nutr."},{"key":"1589_CR27","first-page":"26","volume":"109","author":"\u00c1A Csontos","year":"2017","unstructured":"Csontos \u00c1A, Moln\u00e1r A, Piri Z, P\u00e1lfi E, Miheller P. Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease. Rev Esp Enferm Dig. 2017;109:26\u201332.","journal-title":"Rev Esp Enferm Dig."},{"key":"1589_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nut.2018.12.008","volume":"62","author":"S Jouneau","year":"2019","unstructured":"Jouneau S, Kerjouan M, Rousseau C, Lederlin M, Llamas-Guttierez F, De Latour B, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition. 2019;62:115\u201321.","journal-title":"Nutrition."},{"key":"1589_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.clnu.2016.11.018","volume":"37","author":"AL Rondel","year":"2018","unstructured":"Rondel AL, Langius JA, de van der Schueren MA, Kruizenga HM. The new ESPEN diagnostic criteria for malnutrition predict overall survival in hospitalised patients. Clin Nutr. 2018;37:163\u20138.","journal-title":"Clin Nutr."},{"key":"1589_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clnu.2009.12.004","volume":"29","author":"M Muscaritoli","year":"2010","unstructured":"Muscaritoli M, Anker SD, Argil\u00e9s J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia, and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) \u201ccachexia-anorexia in chronic wasting diseases\u201d and \u201cnutrition in geriatrics. Clin Nutr. 2010;29:154\u20139.","journal-title":"Clin Nutr."},{"key":"1589_CR31","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394:1940\u20138.","journal-title":"Lancet"},{"key":"1589_CR32","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381:1809\u201319.","journal-title":"N Engl J Med"},{"key":"1589_CR33","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/ppul.26485","volume":"58","author":"C Gushue","year":"2023","unstructured":"Gushue C, Eisner M, Bai S, Johnson T, Holtzlander M, McCoy K, et al. Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor on lung disease in cystic fibrosis. Pediatr Pulmonol. 2023;58:2308\u201316.","journal-title":"Pediatr Pulmonol."},{"key":"1589_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcf.2023.05.009","volume":"23","author":"A Wang","year":"2024","unstructured":"Wang A, Lee M, Keller A, Jian S, Lowe K, Finklea JD, et al. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor. J Cys Fibro. 2024;23:91\u20138.","journal-title":"J Cys Fibro."},{"key":"1589_CR35","doi-asserted-by":"publisher","first-page":"2202029","DOI":"10.1183\/13993003.02029-2022","volume":"62","author":"CL Daines","year":"2023","unstructured":"Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, et al. Long-term safety, and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least oneF508delallele: 144-week interim results from a 192-week open-label extension study. Eur Respir J. 2023;62:2202029.","journal-title":"Eur Respir J."},{"key":"1589_CR36","unstructured":"Cystic Fibrosis Trust. Annual Data Report. 2021. www.cysticfibrosis.org.uk\/sites\/default\/files\/2022-10\/CFT_2021-Annual-Data-Report-WEB.pdf. Accessed 25 January 2025."},{"key":"1589_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibro. 2023;22:607\u201314.","journal-title":"J Cyst Fibro."},{"key":"1589_CR38","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/S1569-1993(23)00689-6","volume":"22","author":"L Sasse","year":"2023","unstructured":"Sasse L, Simon A, R\u00fcckes-Nilges C, N\u00e4hrlich L. P319 Effects of elexacaftor\/tezacaftor\/ivacaftor on nutrition parameters and resting energy expenditure in people with cystic fibrosis. J Cyst Fibro. 2023;22:S162.","journal-title":"J Cyst Fibro."},{"key":"1589_CR39","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/ppul.25065","volume":"55","author":"D Munce","year":"2020","unstructured":"Munce D, Lim M, Akong K. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor. Pediatr Pulmonol. 2020;55:3381\u20133.","journal-title":"Pediatr Pulmonol."},{"key":"1589_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jcf.2023.12.001","volume":"23","author":"N Stastna","year":"2023","unstructured":"Stastna N, Pokojova E. Case report of two adults with F508del\/3849+10 kb C > T genotype regaining exocrine pancreatic function following treatment with elexacaftor\/tezacaftor\/ivacaftor. J Cyst Fibro. 2023;23:744\u20135.","journal-title":"J Cyst Fibro."},{"key":"1589_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","volume":"23","author":"JG Mainz","year":"2024","unstructured":"Mainz JG, Lester K, Elnazir B, Williamson M, McKone E, Cox D, et al. Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged \u226512 years \u2013 The RECOVER study. J Cyst Fibro. 2024;23:474\u201380.","journal-title":"J Cyst Fibro."},{"key":"1589_CR42","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S1569-1993(23)00331-4","volume":"22","author":"LR Caley","year":"2023","unstructured":"Caley LR, de Goffau MC, Jones AM, Whitehouse JL, Barrett J, White H, et al. EPS5.01 Change in gut microbiota following elexacaftor\/tezacaftor\/ivacaftor (ETI) therapy: preliminary analysis. J Cyst Fibro. 2023;22:S49.","journal-title":"J Cyst Fibro."},{"key":"1589_CR43","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/nu14061216","volume":"14","author":"J Bailey","year":"2022","unstructured":"Bailey J, Krick S, Fontaine KR. The Changing Landscape of Nutrition in Cystic Fibrosis: The Emergence of Overweight and Obesity. Nutrients. 2022;14:1216\u201334.","journal-title":"Nutrients."},{"key":"1589_CR44","unstructured":"Cystic Fibrosis Trust. Annual Data Report. 2023. www.cysticfibrosis.org.uk\/sites\/default\/files\/2024-11\/CFT_2023_Annual_Data_Report_Oct2024%201.pdf. Accessed 28 January 2025."},{"key":"1589_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89\u2013100.","journal-title":"Syst Rev."},{"key":"1589_CR46","unstructured":"Cochrane. Data collection form: intervention review - RCTs and non-RCTs 2019. https:\/\/training.cochrane.org\/. Accessed 19 April 2023."},{"key":"1589_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101466","volume":"49","author":"V Grancini","year":"2023","unstructured":"Grancini V, Gramegna A, Zazzeron L, Alicandro G, Porcaro LL, Piedepalumbo F, et al. Effects of elexacaftor \/ tezacaftor \/ ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes. Diab Metab. 2023;49:101466.","journal-title":"Diab Metab."},{"key":"1589_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ppul.26243","volume":"58","author":"M Gur","year":"2022","unstructured":"Gur M, Bar-Yoseph R, Hanna M, Abboud D, Keidar Z, Palchan T, et al. Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study. Pediatr Pulmonol. 2022;58:577\u201384.","journal-title":"Pediatr Pulmonol."},{"key":"1589_CR49","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","volume":"42","author":"C Knott-Torcal","year":"2023","unstructured":"Knott-Torcal C, Sebasti\u00e1n-Valles F, Gir\u00f3n Moreno RM, Mart\u00edn-Ad\u00e1n JC, Jim\u00e9nez-D\u00edaz J, Marazuela M, et al. A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation. Clin Nutr. 2023;42:2468\u201374.","journal-title":"Clin Nutr."},{"key":"1589_CR50","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","volume":"22","author":"D Proud","year":"2023","unstructured":"Proud D, Duckers J. Weight a minute: Exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF. J Cyst Fibros. 2023;22:847\u201350.","journal-title":"J Cyst Fibros."},{"key":"1589_CR51","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/ppul.26388","volume":"58","author":"A Granados","year":"2023","unstructured":"Granados A, Chan CL, Moheet A, Vigers T, Arbel\u00e1ez AM, Larson Ode K. The impact of elexacaftor\/tezacaftor\/ivacaftor on body composition in a small cohort of youth with cystic fibrosis. Pediatr Pulmonol. 2023;58:1805\u201311.","journal-title":"Pediatr Pulmonol."},{"key":"1589_CR52","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/advances\/nmab153","volume":"13","author":"SA Purcell","year":"2022","unstructured":"Purcell SA, Oliveira CLP, Mackenzie M, Robson P, Lewis JD, Prado CM. Body Composition and Prostate Cancer Risk: A Systematic Review of Observational Studies. Adv Nutr. 2022;13:1118\u201330.","journal-title":"Adv Nutr."},{"key":"1589_CR53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-023-00943-z","volume":"20","author":"CM Prado","year":"2024","unstructured":"Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol. 2024;20:261\u201377.","journal-title":"Nat Rev Endocrinol."},{"key":"1589_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12970-019-0319-2","volume":"16","author":"O Di Vincenzo","year":"2019","unstructured":"Di Vincenzo O, Marra M, Scalfi L. Bioelectrical impedance phase angle in sport: A systematic review. J Int Soc Sports Nutr. 2019;16:49\u201360.","journal-title":"J Int Soc Sports Nutr."},{"key":"1589_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clnesp.2018.10.010","volume":"29","author":"S Rinaldi","year":"2019","unstructured":"Rinaldi S, Gilliland J, O\u2019Connor C, Chesworth B, Madill J. Is phase angle an appropriate indicator of malnutrition in different disease states? A systematic review. Clin Nutr Espen. 2019;29:1\u20134.","journal-title":"Clin Nutr Espen."},{"key":"1589_CR56","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.3390\/jcm9082554","volume":"9","author":"S Hirose","year":"2020","unstructured":"Hirose S, Nakajima T, Nozawa N, Katayanagi S, Ishizaka H, Mizushima Y, et al. Phase angle as an indicator of sarcopenia, malnutrition, and cachexia in inpatients with cardiovascular diseases. J Clin Med. 2020;9:2554\u201370.","journal-title":"J Clin Med."},{"key":"1589_CR57","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/nutrit\/nuw019","volume":"74","author":"LP Franco","year":"2016","unstructured":"Franco LP, Morais CC, Cominetti C. Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications. Nutr Rev. 2016;74:558\u201370.","journal-title":"Nutr Rev."},{"key":"1589_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2021.100004","volume":"1","author":"AK Fitch","year":"2022","unstructured":"Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures, and telehealth: An Obesity Medicine Association Clinical Practice Statement 2022. Obes Pillars. 2022;1:100004.","journal-title":"Obes Pillars."},{"key":"1589_CR59","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jcf.2023.08.004","volume":"22","author":"C Greaney","year":"2023","unstructured":"Greaney C, Doyle A, Drummond N, King S, Hollander-Kraaijeveld F, Robinson K, et al. What do people with cystic fibrosis eat? Diet quality, macronutrient, and micronutrient intakes (compared to recommended guidelines) in adults with cystic fibrosis\u2013A systematic review. J Cyst Fibros. 2023;22:1036\u201347.","journal-title":"J Cyst Fibros."},{"key":"1589_CR60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","volume":"43","author":"M Wilschanski","year":"2024","unstructured":"Wilschanski M, Munck A, Carrion E, Cipolli M, Collins S, Colombo C, et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin Nutr. 2024;43:413\u201345.","journal-title":"Clin Nutr"}],"container-title":["European Journal of Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41430-025-01589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41430-025-01589-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41430-025-01589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:06:13Z","timestamp":1757153173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41430-025-01589-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1038\/s41430-025-01589-y","relation":{},"ISSN":["0954-3007","1476-5640"],"issn-type":[{"value":"0954-3007","type":"print"},{"value":"1476-5640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}